Glycomimetics Inc. diskutieren
Glycomimetics Inc.
WKN: A1W8HZ / Symbol: GLYC / Name: GlycoMimetics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
Gesundheit | Biotechnologie | Vereinigte Staaten
a + 
Gesundheit | Biotechnologie | Vereinigte Staaten
hat $
GlycoMimetics Is An Exceptional Investment Opportunity
GMI-1271 shows impressive efficacy and safety profile (as of interim Phase 2).
Recent mixed shelf offering hints at major near-term upside potentials.
Longer term, GLYC seems to have found an important biomarker (E-selectin) that may expand TAM exponentially.
FDA Breakthrough Designation will expedite the development process.
Smart institutional investors are behind GLYC as significant long-term investors.
For the longer term, GLYC seems to have found an important biomarker that will allow it to expand into multiple tumor types (key opportunity is multiple myeloma - second largest blood cancer market) - significantly expanding its TAM. This will attract many players in oncology to partner/acquire GLYC once the company proves to be important in AML. In fact, GLYC is already running a Phase 1 trial inmultiple myeloma with GMI-1271 and management has started talking about this opportunity.
Der Beitrag wurde gelöscht
SecteurRecherche biotechnologique et médicale Agenda 26/02 Publication de résultats
glycomimétiques, Inc. fonctionne comme une société de biotechnologie clinique, quiconcentre sur la découverte etdéveloppement de nouveaux médicaments pour répondrebesoins de glycomimétique médicaux non satisfaitsraison de maladies dans lesquellesbiologie des glucides joue un rôle clé.
Il développe des glycomimétiques exclusifs qui inhibent les fonctions des hydrates de carbone liées à la maladie.
La société a été fondée par Rachel K. King et John L. Magnani le 4 avril 2003 et son siège social est situé à Rockville, dans le Maryland.
Nombre d'employés : 40 personnes.
GlycoMimetics is undervalued at current price
The shares are undervalued considering the company has two Phase 3 assets in rivipansel and uproleselan with data for the former expected by the end of Q2. Rivipansel aims to reduce duration of sickle cell disease related pain crises and hospitalization times. The analyst Piper Jaffray views 'the drug as a $1.5B opportunity that is not fully priced into the stock and sees "significant upside from two relatively de-risked programs."
Neueste Beiträge
bundfuture in Annovis Bio Inc. diskutieren